Pembrolizumab approved for use in locally advanced cutaneous SCC in the US
The FDA has granted a licensed extension for pembrolizumab for this indication on the basis of the second interim analysis of the Phase II KEYNOTE-629 trial which found a 50% objective response rate (17% complete response and 33% partial response) with treatment.
Source:
Biospace Inc.